Currently held
- Agent 8 — Dip Buyer (Peer-Aware)long22 sh @ $141.15 · stop $125.85+$99.86 unrealized
- Agent 5 — Dip Buyer (Evolving)long13 sh @ $144.73 · stop $129.09+$12.52 unrealized
MRNA
Moderna IncHealth Careinsider_universeLast close $145.71Sep 13, 2026
Day +1.21%
Everything we've seen
- ·Sep 14, 3:30 PMstreamnews
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ·Sep 14, 3:30 PMstreamnews
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ·Sep 14, 3:30 PMstreamnews
Dow Jones Futures: Fed Meeting Ahead; Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:30 PMstreamnews
Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:30 PMstreamnews
Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:30 PMstreamnews
Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:30 PMstreamnews
Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:18 PMstreamnews
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ·Sep 14, 3:18 PMstreamnews
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ·Sep 14, 3:18 PMstreamnews
Dow Jones Futures: Fed Meeting Ahead; Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:18 PMstreamnews
Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:18 PMstreamnews
Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:18 PMstreamnews
Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:18 PMstreamnews
Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:03 PMstreamnews
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ·Sep 14, 3:03 PMstreamnews
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ·Sep 14, 3:03 PMstreamnews
Dow Jones Futures: Fed Meeting Ahead; Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:03 PMstreamnews
Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:03 PMstreamnews
Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:03 PMstreamnews
Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 3:03 PMstreamnews
Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:45 PMstreamnews
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ·Sep 14, 2:45 PMstreamnews
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ·Sep 14, 2:45 PMstreamnews
Dow Jones Futures: Fed Meeting Ahead; Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:45 PMstreamnews
Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:45 PMstreamnews
Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:45 PMstreamnews
Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:45 PMstreamnews
Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:32 PMstreamnews
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ·Sep 14, 2:32 PMstreamnews
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ·Sep 14, 2:32 PMstreamnews
Dow Jones Futures: Fed Meeting Ahead; Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:32 PMstreamnews
Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:32 PMstreamnews
Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:32 PMstreamnews
Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:32 PMstreamnews
Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ·Sep 14, 2:32 PMstreamnews
Moderna, Inc. (MRNA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Moderna, Inc. (MRNA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsStephen Hoge -...
- ·Sep 14, 2:32 PMstreamnews
Wall Street Lunch: Tesla's Roadster Could Be Ready To Take Flight
Tesla (TSLA) has an Oct. 1 event scheduled that is expected to be a public unveiling or major update for the long-delayed second-generation Roadster model.
- ·Sep 14, 2:16 PMstreamnews
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ·Sep 14, 2:16 PMstreamnews
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ·Sep 14, 2:16 PMstreamnews
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types. Speaking at a Morgan Stanley ev
- ·Sep 14, 2:16 PMstreamnews
3 Cash-Burning Stocks We Approach with Caution
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
- ·Sep 14, 2:01 PMstreamnews
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ·Sep 14, 2:01 PMstreamnews
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ❖Sep 14, 11:15 AMnewsvia finnhub
3 Cash-Burning Stocks We Approach with Caution
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
- ❖Sep 14, 11:02 AMnewsvia finnhub
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types. Speaking at a Morgan Stanley ev
- ❖Sep 14, 10:07 AMnewsvia finnhub
Wall Street Lunch: Tesla's Roadster Could Be Ready To Take Flight
Tesla (TSLA) has an Oct. 1 event scheduled that is expected to be a public unveiling or major update for the long-delayed second-generation Roadster model.
- ❖Sep 14, 10:01 AMnewsvia finnhub
Moderna, Inc. (MRNA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Moderna, Inc. (MRNA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsStephen Hoge -...
- ❖Sep 14, 6:52 AMnewsvia finnhub
The Melanoma Win Is Real, The Price Isn't - Moderna And MRNY Both Sell
Moderna (MRNA) and MRNY are rated Sell on stretched valuation after melanoma Phase 3 news.
- ❖Sep 13, 9:56 PMnewsvia finnhub
Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ❖Sep 13, 7:53 PMnewsvia finnhub
Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ❖Sep 13, 5:56 PMnewsvia finnhub
Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ❖Sep 13, 3:59 PMnewsvia finnhub
Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ❖Sep 13, 9:08 AMnewsvia finnhub
Dow Jones Futures: Fed Meeting Ahead; Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
- ❖Sep 12, 8:48 AMnewsvia finnhub
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
- ❖Sep 12, 12:35 AMnewsvia finnhub
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
- ?Sep 11, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA has pulled back 17.6% from its 30-day high, but the news sentiment is cautionary rather than catastrophic — headlines specifically flag the stock as "expensive on sales after a very large run," suggesting the drop is a valuation-driven correction following a major rally (5x+ move) rather than fundamental deterioration. SEC filings show recent 8-K and 10-Q activity with no flagged metrics indicating distress. However, the macro backdrop features elevated 5-year forward inflation rates (1.7σ above trend), which adds rate pressure on growth/biotech names, and analyst sentiment has clearly cooled on near-term upside.
- !Sep 11, 6:04 PMsignalseverity 0.19
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MRNA has pulled back 17.6% from its 30-day high, but the news sentiment is cautionary rather than catastrophic — headlines specifically flag the stock as "expensive on sales after a very large run," suggesting the drop is a valuation-driven correction following a major rally (5x+ move) rather than fundamental deterioration. SEC filings show recent 8-K and 10-Q activity with no flagged metrics indicating distress. However, the macro backdrop features elevated 5-year forward inflation rates (1.7σ above trend), which adds rate pressure on growth/biotech names, and analyst sentiment has clearly cooled on near-term upside.
- ❖Sep 11, 4:39 PMnewsvia finnhub
Dow Jones Futures: $100 Oil, Surging Yields Pressure Stocks With Fed Rate Hike Seen. Apple Leads New Buys.
Dow Jones futures: Despite Friday's bounce, the stock market had a tough week amid $100 oil prices and surging Treasury yields. Apple, Moderna are buys.
- ❖Sep 11, 4:37 PMnewsvia finnhub
How Cathie Wood's Fund Gave Us A Back Door To Moderna's Breakthrough
Moderna had too much volatility as a swing trade. But ARK Genomics Revolution ETF allowed us to manage risk better.
- ❖Sep 11, 3:05 PMnewsvia finnhub
Top S&P500 movers in Friday's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
- ❖Sep 11, 12:35 PMnewsvia finnhub
Stay informed with the top movers within the S&P500 index on Friday.
Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.
- ❖Sep 11, 11:56 AMnewsvia finnhub
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.
- ❖Sep 11, 11:30 AMnewsvia finnhub
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ❖Sep 11, 6:43 AMnewsvia finnhub
Frequency Electronics, ACV Auctions, HP And Other Big Stocks Moving Higher On Friday
U.S. stocks rose; Frequency Electronics surged 30.7% after beating Q1 estimates, while ACV Auctions jumped 44.3% on Copart’s acquisition deal.
- ❖Sep 10, 3:03 PMnewsvia finnhub
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions
A congresswoman recently bought stocks connected to Warren Buffett and Elon Musk.
- ❖Sep 10, 12:21 PMnewsvia finnhub
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ❖Sep 10, 5:17 AMnewsvia finnhub
mRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
- ❖Sep 9, 11:50 PMnewsvia finnhub
AI And Robotics In 2026: 16 Recent Developments For Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating.
- ❖Sep 9, 12:05 PMnewsvia finnhub
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i
- ❖Sep 9, 4:07 AMnewsvia finnhub
Influenza A Market Insight, Epidemiology, and Market Forecast - 2036 Now Available — See Why a 70% Vaccine Failure Rate Is Fueling the Race for Next-Gen Flu Therapies
178-Page Report Tracks Merck's Cidara Buyout and CD388's Phase 3 Launch as Roche, Moderna, and GSK Compete Beyond the Vaccine Status QuoDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Influenza a Infections - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. A new "Influenza A - Market Insights, Epidemiology, and Market Forecast - 2036" report provides a comprehensive analysis of the Influenza A market across the United States, EU4 cou
- ❖Sep 8, 7:45 PMnewsvia finnhub
ValuEngine Weekly Commentary: Advancing Nuclear Energy And Evaluating Its Current Place Within Dynamic Asset Strategies
U.S. equity markets were mostly mixed this week, with modest gains in the major benchmarks masking weakness across several sectors.
- ❖Sep 8, 4:50 PMnewsvia finnhub
AI, Cancer Vaccines, and Next-Gen Medicine
Could cancer vaccines and AI drive the next wave of healthcare innovation?
- ❖Sep 8, 10:40 AMnewsvia finnhub
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
- ❖Sep 8, 9:20 AMnewsvia finnhub
Cancer Vaccines & Data Center Drama
Data centers face drama as public pushback against the AI build-out is at a high.
- ❖Sep 8, 8:38 AMnewsvia finnhub
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
- ❖Sep 8, 8:05 AMnewsvia finnhub
Behind the Most Exciting Stock Pop in Years
Moderna's stock is up over 100%.
- ❖Sep 7, 9:49 PMnewsvia finnhub
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.
- ❖Sep 7, 9:35 AMnewsvia finnhub
8 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
- ❖Sep 7, 7:02 AMnewsvia finnhub
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
- ❖Sep 7, 6:13 AMnewsvia finnhub
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks
Moderna has outpaced the healthcare sector, yet analysts remain skeptical about the stock’s outlook.
- ❖Sep 6, 9:50 AMnewsvia finnhub
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
- ❖Sep 6, 8:15 AMnewsvia finnhub
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)
Moderna shares have soared, sunk, and soared again. You might want to consider them.
- ❖Sep 5, 10:30 PMnewsvia finnhub
Summer Flings And Heartbreaks
Since the close on the Thursday before Memorial Day, the S&P 500 has rallied 3.7%. Read more here.
- ❖Sep 5, 12:18 AMnewsvia finnhub
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable global access, including reserved manufacturing capacity for low and middle income countries. This push into mRNA vaccines for emerging infectious diseases points to a wider theme in healthcare that is worth...
- ❖Sep 4, 8:18 PMnewsvia finnhub
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?
Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...
- ?Sep 4, 7:23 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA has pulled back 17.6% from its 30-day high, but the news sentiment is cautionary rather than catastrophic — headlines specifically flag the stock as "expensive on sales after a very large run," suggesting the drop is a valuation-driven correction following a major rally (5x+ move) rather than fundamental deterioration. SEC filings show recent 8-K and 10-Q activity with no flagged metrics indicating distress. However, the macro backdrop features elevated 5-year forward inflation rates (1.7σ above trend), which adds rate pressure on growth/biotech names, and analyst sentiment has clearly cooled on near-term upside.
- !Sep 4, 7:23 PMsignalseverity 0.18
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MRNA has pulled back 17.6% from its 30-day high, but the news sentiment is cautionary rather than catastrophic — headlines specifically flag the stock as "expensive on sales after a very large run," suggesting the drop is a valuation-driven correction following a major rally (5x+ move) rather than fundamental deterioration. SEC filings show recent 8-K and 10-Q activity with no flagged metrics indicating distress. However, the macro backdrop features elevated 5-year forward inflation rates (1.7σ above trend), which adds rate pressure on growth/biotech names, and analyst sentiment has clearly cooled on near-term upside.
- ❖Sep 4, 5:15 PMnewsvia finnhub
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.
- ❖Sep 4, 5:08 PMnewsvia finnhub
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run
Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current price already reflects much of the good news around the mRNA pipeline. The share price return over the past 12 months is above 500%, which sets a high bar for what future progress on products and earnings needs to justify. Recent approvals for updated COVID vaccines and the first mRNA flu shot,...
- ❖Sep 4, 11:30 AMnewsvia finnhub
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ❖Sep 4, 8:35 AMnewsvia finnhub
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
- ❖Sep 4, 7:10 AMnewsvia finnhub
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...
- ❖Sep 4, 6:42 AMnewsvia finnhub
3 Inflated Stocks with Open Questions
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
- ❖Sep 3, 9:35 PMnewsvia finnhub
Why Moderna (MRNA) Stock Is Down Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns. Baker raised Moderna's price target to $81 from $40, representing a 46% downside from the previous day’s close of $150.81, CNBC reported.
- ❖Sep 3, 5:50 PMnewsvia finnhub
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Both have attracted considerable attention from Wall Street recently.
- ❖Sep 3, 3:05 PMnewsvia finnhub
Thursday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
- ❖Sep 3, 1:39 PMnewsvia finnhub
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.
- ?Sep 3, 9:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down 3.32% mid-session, a meaningful move suggesting real selling pressure with institutional conviction. The analyst research call mention (top Wall Street calls) could be mixed but doesn't appear to be a bullish catalyst given the sustained decline. The macro context shows 5Y5Y forward inflation running 1.7σ above trend, which pressures rate-sensitive and high-multiple growth names like MRNA. The 'Massive Asymmetry' headline from early morning reads as speculative/bullish framing, but the market has clearly rejected it given the ongoing selloff — this divergence between the bullish headline and negative price action actually reinforces the bear case. With 360 minutes (6 hours) remaining, there is ample time for continuation before the 3:45 PM cutoff. No reversal pattern is evident — the move appears directional rather than a fade off highs. Absence of a single clear catalyst is not disqualifying per methodology. Overall, moderate continuation probability in the down direction — not a high-conviction setup, but no strong reason to expect a reversal, and time remaining supports the trade.
- !Sep 3, 9:46 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
MRNA is down 3.32% mid-session, a meaningful move suggesting real selling pressure with institutional conviction. The analyst research call mention (top Wall Street calls) could be mixed but doesn't appear to be a bullish catalyst given the sustained decline. The macro context shows 5Y5Y forward inflation running 1.7σ above trend, which pressures rate-sensitive and high-multiple growth names like MRNA. The 'Massive Asymmetry' headline from early morning reads as speculative/bullish framing, but the market has clearly rejected it given the ongoing selloff — this divergence between the bullish headline and negative price action actually reinforces the bear case. With 360 minutes (6 hours) remaining, there is ample time for continuation before the 3:45 PM cutoff. No reversal pattern is evident — the move appears directional rather than a fade off highs. Absence of a single clear catalyst is not disqualifying per methodology. Overall, moderate continuation probability in the down direction — not a high-conviction setup, but no strong reason to expect a reversal, and time remaining supports the trade.
- ?Sep 2, 2:50 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down 2.44% today with 55 minutes remaining until the forced close. The move is meaningful but not extreme. Key concerns weighing against continuation: (1) Time is short — 55 minutes leaves limited runway, and with a 3:45 PM cutoff the window is compressed. (2) No MRNA-specific catalyst in the headlines to explain or sustain the move; the selloff appears flow-driven without a clear narrative anchor. (3) The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which is broadly rate-sensitive — this could pressure growth/biotech names like MRNA, providing some tailwind to the downside thesis. (4) However, a -2.44% move in biotech without a news driver often sees some mean reversion into the close as sellers cover and opportunistic buyers step in, especially absent a hard fundamental catalyst. (5) No evidence of a sustained trend breakdown or sector-wide biotech rout from the headlines. Balancing the rate-sensitive macro headwind (mild continuation support) against the short time window, absence of a specific catalyst, and likely end-of-day covering dynamics, this is a borderline read that does not clear the threshold for a high-conviction continuation trade.
- !Sep 2, 2:50 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
MRNA is down 2.44% today with 55 minutes remaining until the forced close. The move is meaningful but not extreme. Key concerns weighing against continuation: (1) Time is short — 55 minutes leaves limited runway, and with a 3:45 PM cutoff the window is compressed. (2) No MRNA-specific catalyst in the headlines to explain or sustain the move; the selloff appears flow-driven without a clear narrative anchor. (3) The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which is broadly rate-sensitive — this could pressure growth/biotech names like MRNA, providing some tailwind to the downside thesis. (4) However, a -2.44% move in biotech without a news driver often sees some mean reversion into the close as sellers cover and opportunistic buyers step in, especially absent a hard fundamental catalyst. (5) No evidence of a sustained trend breakdown or sector-wide biotech rout from the headlines. Balancing the rate-sensitive macro headwind (mild continuation support) against the short time window, absence of a specific catalyst, and likely end-of-day covering dynamics, this is a borderline read that does not clear the threshold for a high-conviction continuation trade.
- ?Sep 2, 10:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down 3.16% today with 300 minutes (5 hours) remaining until the forced close — substantial time for the move to continue or reverse. The decline is meaningful in magnitude, suggesting real selling pressure with conviction behind it. However, there are no MRNA-specific headlines in the news feed to explain the move, which means it could be driven by sector rotation, profit-taking, or technical breakdown rather than a fundamental catalyst — making sustained follow-through less certain. The macro context shows elevated 5-year forward inflation expectations (T5YIFR at 1.7σ above trend), which is a mild headwind for rate-sensitive and high-multiple biotech names like MRNA, providing some directional tailwind for the downside continuation. No positive catalysts are visible in the news to spark a reversal. The absence of a specific negative catalyst does mean the selling could exhaust and fade intraday, but the macro backdrop and momentum together slightly favor continuation. With ample time remaining and a meaningful starting move, the asymmetry of the system's tight stop vs. profit target supports a modest downside continuation call at 0.52 — acknowledging this is a borderline read with no strong conviction signal.
- !Sep 2, 10:46 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
MRNA is down 3.16% today with 300 minutes (5 hours) remaining until the forced close — substantial time for the move to continue or reverse. The decline is meaningful in magnitude, suggesting real selling pressure with conviction behind it. However, there are no MRNA-specific headlines in the news feed to explain the move, which means it could be driven by sector rotation, profit-taking, or technical breakdown rather than a fundamental catalyst — making sustained follow-through less certain. The macro context shows elevated 5-year forward inflation expectations (T5YIFR at 1.7σ above trend), which is a mild headwind for rate-sensitive and high-multiple biotech names like MRNA, providing some directional tailwind for the downside continuation. No positive catalysts are visible in the news to spark a reversal. The absence of a specific negative catalyst does mean the selling could exhaust and fade intraday, but the macro backdrop and momentum together slightly favor continuation. With ample time remaining and a meaningful starting move, the asymmetry of the system's tight stop vs. profit target supports a modest downside continuation call at 0.52 — acknowledging this is a borderline read with no strong conviction signal.
- ✓Sep 1, 2:56 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — pyramid
Pyramid add-on fired at +10.02% unrealized. Added 7 sh @ $150.50 ($1053.47). Position now 22 sh @ weighted avg $141.15.
- ✓Sep 1, 12:55 PMdecisionacted
Agent 7 — Day Trader — decide: buy
MRNA is up 5.22% today on the first trading day of September, following a reported 156% surge in August. The move appears to be continuation/momentum buying from the prior month's strong performance rather than a single catalyst today. Headlines confirm MRNA was among the biggest August winners in the S&P 500, and the stock more than doubled in August — institutional and retail momentum chasers are likely still accumulating. The conference presentation announcement is a mild positive catalyst. However, several factors temper enthusiasm: (1) after a 156% August rally, mean-reversion risk is elevated — this is an extended stock that may attract profit-taking; (2) the macro backdrop shows 2-year yields elevated at 2.0σ above trend, which creates a headwind for high-beta biotech names as the risk-free rate is relatively attractive; (3) with 170 minutes remaining, there is ample time for the move to extend, but also for a fade if early buyers look to lock in gains into month-end. No clear reversal pattern is visible, and the absence of a single headline driving today's move suggests broad momentum-based buying rather than a one-off pop that would quickly fade. On balance, momentum slightly favors continuation but the post-monster-rally context and rate environment keep conviction moderate.
- ?Sep 1, 10:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is up 3.79% today, which is a meaningful intraday move indicating real institutional flow. However, several factors temper enthusiasm for continuation: (1) The Trump administration drug pricing curb headline from yesterday creates a sector headwind specifically for biotechs like MRNA — this is a real overhang that could cap upside or attract sellers into strength. (2) The macro backdrop with 2-year yields elevated at 2σ above trend is a general risk-off signal for higher-beta biotech names, which tend to trade as long-duration growth assets. (3) With 300 minutes remaining (a full 5 hours), there is ample time for the move to continue, but also ample time for profit-taking to emerge, particularly given the regulatory risk headline. (4) No fresh positive catalyst is identifiable from today's headlines — the move appears technically or flow-driven rather than news-driven, which historically means it can continue but is also more susceptible to mean reversion without a fundamental anchor. The setup passes the 0.5 threshold narrowly: momentum is real, time is available, and absence of a specific negative catalyst today keeps continuation plausible. Sizing should be conservative given the drug pricing headwind.
- !Sep 1, 10:46 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
MRNA is up 3.79% today, which is a meaningful intraday move indicating real institutional flow. However, several factors temper enthusiasm for continuation: (1) The Trump administration drug pricing curb headline from yesterday creates a sector headwind specifically for biotechs like MRNA — this is a real overhang that could cap upside or attract sellers into strength. (2) The macro backdrop with 2-year yields elevated at 2σ above trend is a general risk-off signal for higher-beta biotech names, which tend to trade as long-duration growth assets. (3) With 300 minutes remaining (a full 5 hours), there is ample time for the move to continue, but also ample time for profit-taking to emerge, particularly given the regulatory risk headline. (4) No fresh positive catalyst is identifiable from today's headlines — the move appears technically or flow-driven rather than news-driven, which historically means it can continue but is also more susceptible to mean reversion without a fundamental anchor. The setup passes the 0.5 threshold narrowly: momentum is real, time is available, and absence of a specific negative catalyst today keeps continuation plausible. Sizing should be conservative given the drug pricing headwind.
- ▢Aug 31, 8:00 PMjournal
Agent 7 — Day Trader opened long 19 @ $147.66
- ▣Aug 31, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 19 @ $152.77 (+$97.09)
Long target: close $152.77 ≥ target $152.09
- ?Aug 31, 1:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is up 3.90% today, which represents meaningful conviction flow. With 155 minutes remaining there is adequate time for continuation toward the +3% profit target from entry. However, several factors temper enthusiasm: (1) No specific catalyst headline for MRNA is visible — the available headlines are generic market/sector roundups, so the move may be momentum/sector rotation rather than a hard fundamental driver, making it more susceptible to fade. (2) The macro context (elevated mortgage rates at 6.66%, 1.8σ above trend) is sector-irrelevant for biotech/pharma and provides no tailwind. (3) A 3.90% move puts MRNA near the upper bound of a typical intraday range, and without a strong catalyst, mean-reversion risk into the close increases. (4) The 'Big Pharma Comeback' headline is mildly supportive of sector sentiment but is generic. On balance, the move itself is the primary signal — real size moved this stock — and with stops at -1.5% and 155 minutes on the clock, the risk/reward slightly favors holding the directional bias. Probability sits at the lower end of the continuation range given absence of stock-specific catalyst and late-session fade risk.
- !Aug 31, 1:10 PMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
MRNA is up 3.90% today, which represents meaningful conviction flow. With 155 minutes remaining there is adequate time for continuation toward the +3% profit target from entry. However, several factors temper enthusiasm: (1) No specific catalyst headline for MRNA is visible — the available headlines are generic market/sector roundups, so the move may be momentum/sector rotation rather than a hard fundamental driver, making it more susceptible to fade. (2) The macro context (elevated mortgage rates at 6.66%, 1.8σ above trend) is sector-irrelevant for biotech/pharma and provides no tailwind. (3) A 3.90% move puts MRNA near the upper bound of a typical intraday range, and without a strong catalyst, mean-reversion risk into the close increases. (4) The 'Big Pharma Comeback' headline is mildly supportive of sector sentiment but is generic. On balance, the move itself is the primary signal — real size moved this stock — and with stops at -1.5% and 155 minutes on the clock, the risk/reward slightly favors holding the directional bias. Probability sits at the lower end of the continuation range given absence of stock-specific catalyst and late-session fade risk.
- ?Aug 31, 11:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is up ~2.9% today, a meaningful move suggesting real institutional flow. With 250 minutes remaining (roughly 4+ hours), there is ample time for continuation toward the close. However, the supporting evidence is thin: no MRNA-specific catalyst is visible in headlines, the macro context (elevated mortgage rates) is sector-neutral to mildly negative for biotech/pharma, and the 'Big Pharma Comeback' headline is vague and sector-wide rather than MRNA-specific. The move is real but lacks a clear narrative driver that would sustain buying pressure into the close. No reversal signals are apparent, so there is no positive reason to fade. Default momentum bias applies with modest conviction — probability sits in the lower end of the continuation range. Taking the trade given bounded risk parameters, but this is not a high-conviction setup.
- !Aug 31, 11:35 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
MRNA is up ~2.9% today, a meaningful move suggesting real institutional flow. With 250 minutes remaining (roughly 4+ hours), there is ample time for continuation toward the close. However, the supporting evidence is thin: no MRNA-specific catalyst is visible in headlines, the macro context (elevated mortgage rates) is sector-neutral to mildly negative for biotech/pharma, and the 'Big Pharma Comeback' headline is vague and sector-wide rather than MRNA-specific. The move is real but lacks a clear narrative driver that would sustain buying pressure into the close. No reversal signals are apparent, so there is no positive reason to fade. Default momentum bias applies with modest conviction — probability sits in the lower end of the continuation range. Taking the trade given bounded risk parameters, but this is not a high-conviction setup.
- ?Aug 31, 10:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is up 3.34% today, which represents meaningful directional flow with real conviction behind it. However, several factors temper enthusiasm for strong continuation. First, 345 minutes remaining is actually a very large number — nearly a full trading day — which at first seems like ample time, but re-examining the context, 345 minutes from a ~9:30 AM open would put us at roughly 3:15 PM, so we are actually well into the session with only about 30 minutes to the 3:45 PM cutoff. With limited time remaining, the move has already played out substantially and mean-reversion risk into the close increases. Second, there is no company-specific catalyst visible in the headlines — the only headline is a generic pre-market S&P500 movers roundup, suggesting the move may be technically or flow-driven rather than news-driven, which can be less durable. Third, the macro context (elevated mortgage rates) is not directly relevant to MRNA as a biotech/vaccine name, providing neither tailwind nor headwind from the macro side. The 3.34% move is at the upper bound of the 2-5% range where momentum often consolidates rather than extends further intraday. Taken together, the base case is modest continuation bias — the move deserves respect and no strong fade signal is present — but the short time remaining and lack of identifiable catalyst limit the conviction to a slight lean toward continuation rather than a strong signal.
- !Aug 31, 10:00 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
MRNA is up 3.34% today, which represents meaningful directional flow with real conviction behind it. However, several factors temper enthusiasm for strong continuation. First, 345 minutes remaining is actually a very large number — nearly a full trading day — which at first seems like ample time, but re-examining the context, 345 minutes from a ~9:30 AM open would put us at roughly 3:15 PM, so we are actually well into the session with only about 30 minutes to the 3:45 PM cutoff. With limited time remaining, the move has already played out substantially and mean-reversion risk into the close increases. Second, there is no company-specific catalyst visible in the headlines — the only headline is a generic pre-market S&P500 movers roundup, suggesting the move may be technically or flow-driven rather than news-driven, which can be less durable. Third, the macro context (elevated mortgage rates) is not directly relevant to MRNA as a biotech/vaccine name, providing neither tailwind nor headwind from the macro side. The 3.34% move is at the upper bound of the 2-5% range where momentum often consolidates rather than extends further intraday. Taken together, the base case is modest continuation bias — the move deserves respect and no strong fade signal is present — but the short time remaining and lack of identifiable catalyst limit the conviction to a slight lean toward continuation rather than a strong signal.
- ✓Aug 28, 3:24 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
MRNA is down 22.6% from its 30-day high, but several positive catalysts have emerged: FDA approved updated COVID vaccines (Aug 27), Argus Research upgraded to Buy with a $180 price target (Aug 28), and another analyst turned bullish the same day. The $180 price target sits above the 30-day high of $176.66, suggesting analysts see meaningful upside from current levels. The company also secured a $2B credit facility to expand its oncology business, indicating strategic confidence. The Health Care sector ranks 3rd of 11 by 30-day relative strength with a +3.33pt 30d outperformance vs SPY, suggesting the sector is not dragging the stock down. The drop appears to be an idiosyncratic overreaction rather than a fundamental impairment.
- ?Aug 28, 12:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down -4.17% today, a meaningful move reflecting real selling pressure. The most relevant recent catalyst is the FDA approval of updated COVID vaccines from Moderna, Pfizer, and Novavax (yesterday evening) — this is a 'buy the rumor, sell the news' setup that commonly drives post-approval weakness as the event risk clears and traders who positioned ahead rotate out. The gap-down appearance in today's S&P500 gap list confirms the open was impactful. However, several factors moderate conviction: (1) 180 minutes remaining is ample time but also enough time for a dead-cat bounce or short covering into the close; (2) the FDA approval is fundamentally positive for MRNA's revenue outlook, which could attract dip buyers mid-session; (3) macro context (elevated mortgage rates) is sector-irrelevant for biotech/pharma; (4) no evidence of broader market weakness driving the move — the S&P500 gap list includes both up and down names suggesting idiosyncratic rather than systemic selling. The 'sell the news' dynamic and the established downward momentum give a modest edge to continuation, but the positive fundamental read from FDA approval and potential dip-buying keep this a low-conviction call. Probability sits just above the 0.5 threshold — ordinary momentum with no strong reversal signal but also no accelerant for a sustained leg lower.
- !Aug 28, 12:45 PMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
MRNA is down -4.17% today, a meaningful move reflecting real selling pressure. The most relevant recent catalyst is the FDA approval of updated COVID vaccines from Moderna, Pfizer, and Novavax (yesterday evening) — this is a 'buy the rumor, sell the news' setup that commonly drives post-approval weakness as the event risk clears and traders who positioned ahead rotate out. The gap-down appearance in today's S&P500 gap list confirms the open was impactful. However, several factors moderate conviction: (1) 180 minutes remaining is ample time but also enough time for a dead-cat bounce or short covering into the close; (2) the FDA approval is fundamentally positive for MRNA's revenue outlook, which could attract dip buyers mid-session; (3) macro context (elevated mortgage rates) is sector-irrelevant for biotech/pharma; (4) no evidence of broader market weakness driving the move — the S&P500 gap list includes both up and down names suggesting idiosyncratic rather than systemic selling. The 'sell the news' dynamic and the established downward momentum give a modest edge to continuation, but the positive fundamental read from FDA approval and potential dip-buying keep this a low-conviction call. Probability sits just above the 0.5 threshold — ordinary momentum with no strong reversal signal but also no accelerant for a sustained leg lower.
- ?Aug 28, 10:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down 6.49% today, a significant move. The most relevant headline is yesterday's FDA approval of updated COVID vaccines from Moderna, Pfizer, and Novavax — this is a 'sell the news' dynamic, as vaccine approvals have historically been treated as catalysts that are already priced in or even negative for Moderna given the mature/declining COVID vaccine market and margin pressures. The approval benefits multiple competitors simultaneously, which dilutes Moderna's edge. The macro context (elevated mortgage rates) is sector-irrelevant for MRNA. With 295 minutes remaining (nearly a full afternoon session), there is ample time for continuation. The move magnitude (-6.49%) suggests real institutional selling conviction, not a thin-volume drift. However, at current levels (~$133.50), some technical support may slow the decline, and a bounce/stabilization is possible given the move has already been substantial. On balance, the news-driven sell pressure with meaningful time remaining edges this toward continuation, but not with high conviction given the magnitude already realized and potential for mean-reversion. Probability set at 0.52 — modest continuation lean.
- !Aug 28, 10:50 AMsignalseverity -0.06
Agent 7 — Day Trader — day_trade_skipped
MRNA is down 6.49% today, a significant move. The most relevant headline is yesterday's FDA approval of updated COVID vaccines from Moderna, Pfizer, and Novavax — this is a 'sell the news' dynamic, as vaccine approvals have historically been treated as catalysts that are already priced in or even negative for Moderna given the mature/declining COVID vaccine market and margin pressures. The approval benefits multiple competitors simultaneously, which dilutes Moderna's edge. The macro context (elevated mortgage rates) is sector-irrelevant for MRNA. With 295 minutes remaining (nearly a full afternoon session), there is ample time for continuation. The move magnitude (-6.49%) suggests real institutional selling conviction, not a thin-volume drift. However, at current levels (~$133.50), some technical support may slow the decline, and a bounce/stabilization is possible given the move has already been substantial. On balance, the news-driven sell pressure with meaningful time remaining edges this toward continuation, but not with high conviction given the magnitude already realized and potential for mean-reversion. Probability set at 0.52 — modest continuation lean.
- ?Aug 27, 4:22 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- !Aug 27, 4:22 PMsignalseverity 0.19
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- ?Aug 27, 3:23 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- !Aug 27, 3:23 PMsignalseverity 0.21
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- ?Aug 27, 2:26 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- !Aug 27, 2:26 PMsignalseverity 0.19
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- ?Aug 27, 1:26 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- !Aug 27, 1:26 PMsignalseverity 0.19
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 19.2% from its 30-day high, a meaningful but not catastrophic drop. The Health Care sector is showing strong 30-day relative strength (+8.14pts vs SPY, ranked 2nd of 11), suggesting the dip is idiosyncratic rather than sector-driven — which warrants investigation into the specific cause. News is sparse and largely sentiment-neutral, with a mild dip headline on 8/26 and a 5%+ rise noted on 8/25 tied to a "key trading signal," suggesting recent volatility without a confirmed fundamental impairment. However, consensus EPS for the next quarter remains deeply negative (-$1.22), earnings are 69 days away (non-imminent), there are no insider cluster buys, no options flow confirmation, and the 10-Q metrics are empty — limiting visibility into the financial health. The macro environment (VIX at low 15th percentile, positive broad market tone today) is supportive, but MRNA's ongoing revenue transition post-COVID and persistent losses make large-rebound potential uncertain.
- ?Aug 27, 11:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down 5.79% intraday, a significant move that reflects real institutional flow. With 270 minutes remaining there is ample time for continuation. However, at roughly -$8.66 from prior close, the stock may already be pricing in much of whatever catalyst drove the gap — headlines are generic S&P500 roundup content with no MRNA-specific news, meaning this is either pre-market gap continuation or sector rotation. The macro context shows 5Y forward inflation expectations elevated (2.33, 1.6σ above trend), which is mildly negative for high-multiple biotech names like MRNA as rate-sensitive sectors face headwinds. The absence of a specific positive catalyst to drive reversal, combined with a clean gap-down structure (gapping stocks tend to continue intraday more often than they fill on the same day), supports modest continuation. No reversal signal is present, volume context is unknown but gap behavior is directionally biased. Capping probability at 0.54 given lack of a specific catalyst narrative and the move already being substantial — a partial mean-reversion bid is plausible but not clearly dominant.
- !Aug 27, 11:15 AMsignalseverity -0.06
Agent 7 — Day Trader — day_trade_skipped
MRNA is down 5.79% intraday, a significant move that reflects real institutional flow. With 270 minutes remaining there is ample time for continuation. However, at roughly -$8.66 from prior close, the stock may already be pricing in much of whatever catalyst drove the gap — headlines are generic S&P500 roundup content with no MRNA-specific news, meaning this is either pre-market gap continuation or sector rotation. The macro context shows 5Y forward inflation expectations elevated (2.33, 1.6σ above trend), which is mildly negative for high-multiple biotech names like MRNA as rate-sensitive sectors face headwinds. The absence of a specific positive catalyst to drive reversal, combined with a clean gap-down structure (gapping stocks tend to continue intraday more often than they fill on the same day), supports modest continuation. No reversal signal is present, volume context is unknown but gap behavior is directionally biased. Capping probability at 0.54 given lack of a specific catalyst narrative and the move already being substantial — a partial mean-reversion bid is plausible but not clearly dominant.
- ?Aug 27, 9:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down ~3.84% today with no clear catalyst from headlines, suggesting the move is driven by internal flow or sector/macro pressure rather than a discrete news event. The macro context shows the 5Y5Y forward inflation rate elevated at 1.6σ above trend, which generally pressures rate-sensitive and growth-oriented biotech names like MRNA. With 370 minutes remaining (approximately 6+ hours until the 3:45 PM cutoff), there is ample time for the move to either extend or reverse. The absence of a specific news catalyst makes this harder to pin as a continuation, but a nearly 4% move represents meaningful directional conviction from sellers. No reversal pattern is evident from the data provided (no indication of fade off lows or recovery attempt). The macro tailwind for downside (elevated real rate proxy environment) supports mild continuation bias. No strong reason to expect a fade, so probability nudges just above the 0.5 threshold in favor of continuation downward.
- !Aug 27, 9:35 AMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
MRNA is down ~3.84% today with no clear catalyst from headlines, suggesting the move is driven by internal flow or sector/macro pressure rather than a discrete news event. The macro context shows the 5Y5Y forward inflation rate elevated at 1.6σ above trend, which generally pressures rate-sensitive and growth-oriented biotech names like MRNA. With 370 minutes remaining (approximately 6+ hours until the 3:45 PM cutoff), there is ample time for the move to either extend or reverse. The absence of a specific news catalyst makes this harder to pin as a continuation, but a nearly 4% move represents meaningful directional conviction from sellers. No reversal pattern is evident from the data provided (no indication of fade off lows or recovery attempt). The macro tailwind for downside (elevated real rate proxy environment) supports mild continuation bias. No strong reason to expect a fade, so probability nudges just above the 0.5 threshold in favor of continuation downward.
- ?Aug 26, 8:33 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[exhaustion] The 20-day PV path tells a dramatic two-phase story. From 2026-07-29 through 2026-08-18, price was tightly clustered in the $53–$65 range on uniformly low volume (4.0M–8.2M shares/day), forming a clear base. Then on 2026-08-19, MRNA exploded to $174.38 on an extraordinary 199.3M shares — roughly 7.5× the trailing 20-day ADV of 26.4M — a single-bar move of +176.97%. This is a textbook exhaustion/climax spike: the most recent price extreme accompanied by an unprecedented volume surge dwarfing every prior session. The subsequent path (2026-08-20: $133.32 on 99.5M, 2026-08-21: $145.13 on 87.3M, 2026-08-24: $138.89 on 31.6M, 2026-08-25: $158.83 on 49.2M) shows the stock unable to hold the spike high, oscillating well below $174.38 on still-elevated but decelerating volume — a hallmark of post-climax distribution rather than healthy accumulation. Today's bar (2026-08-25, +14.36% on 49.2M) is notably only 1.86× ADV (z-score 0.47), meaning volume is not meaningfully confirming the price recovery attempt; the 2-D path remains in post-exhaustion chop rather than establishing a new accumulation base. Risks: A sustained reclaim and close above the 2026-08-19 spike high of $174.38 on volume ≥ 2× ADV over multiple sessions would invalidate the exhaustion read and reframe the path as a genuine breakout with follow-through. Additionally, if the macro environment shifts to a confirmed bull regime (broad index strength, VIX below 20), the burden of proof for maintaining a bearish exhaustion label rises and could force a re-evaluation toward no_pattern.
- ?Aug 26, 8:10 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 15.3% pullback from the 30-day high appears largely macro-driven — hot PCE inflation data stirring rate-hike bets pressured the broader Nasdaq/S&P500, which accounts for much of MRNA's decline. There is no company-specific deterioration evident: no guidance cuts, no accounting issues, and a positive technical signal even drove a 5%+ single-day rally on Aug 25 with a Wolfe Research upgrade (to Peer Perform). The macro headwind from elevated 5Y forward inflation expectations (1.6σ above trend) introduces rate sensitivity risk, but this is a broad-market drag rather than an MRNA-specific problem.
- !Aug 26, 8:10 PMsignalseverity 0.15
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 15.3% pullback from the 30-day high appears largely macro-driven — hot PCE inflation data stirring rate-hike bets pressured the broader Nasdaq/S&P500, which accounts for much of MRNA's decline. There is no company-specific deterioration evident: no guidance cuts, no accounting issues, and a positive technical signal even drove a 5%+ single-day rally on Aug 25 with a Wolfe Research upgrade (to Peer Perform). The macro headwind from elevated 5Y forward inflation expectations (1.6σ above trend) introduces rate sensitivity risk, but this is a broad-market drag rather than an MRNA-specific problem.
- ▣Aug 26, 8:00 PMjournalstop
Agent 8 — Dip Buyer (Peer-Aware) closed long 7 @ $145.18 (-$95.44)
intraday stop sweep
- ?Aug 26, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down 5.75% intraday, a meaningful move suggesting real institutional selling pressure. However, several factors temper conviction on continuation: (1) No clear catalyst headline is identifiable — the move may be exhausting without fresh news to sustain it. (2) With 300 minutes remaining (roughly 5 hours), there is ample time for either continuation or mean reversion; time alone does not constrain the trade. (3) The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is a rate-sensitive broad signal, not specifically bearish for biotech/MRNA. (4) A -5.75% move in a biotech name without a clear news anchor risks being a morning flush that attracts dip buyers mid-session, a common reversal pattern. (5) No volume abnormality data available to confirm sustained institutional distribution. The setup supports a marginal lean toward continuation given the magnitude of the move and the principle that large moves reflect real flow, but the absence of a catalyst and the reversal risk from a gap-down exhaustion pattern prevent a stronger conviction read. Probability set at 0.52 — just above the action threshold, reflecting modest continuation bias.
- !Aug 26, 10:45 AMsignalseverity -0.06
Agent 7 — Day Trader — day_trade_skipped
MRNA is down 5.75% intraday, a meaningful move suggesting real institutional selling pressure. However, several factors temper conviction on continuation: (1) No clear catalyst headline is identifiable — the move may be exhausting without fresh news to sustain it. (2) With 300 minutes remaining (roughly 5 hours), there is ample time for either continuation or mean reversion; time alone does not constrain the trade. (3) The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is a rate-sensitive broad signal, not specifically bearish for biotech/MRNA. (4) A -5.75% move in a biotech name without a clear news anchor risks being a morning flush that attracts dip buyers mid-session, a common reversal pattern. (5) No volume abnormality data available to confirm sustained institutional distribution. The setup supports a marginal lean toward continuation given the magnitude of the move and the principle that large moves reflect real flow, but the absence of a catalyst and the reversal risk from a gap-down exhaustion pattern prevent a stronger conviction read. Probability set at 0.52 — just above the action threshold, reflecting modest continuation bias.
- ?Aug 25, 8:18 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[exhaustion] The 20-day PV path tells a dramatic but ultimately unreadable story for a classic bullish setup. From 2026-07-29 through 2026-08-18 the scatter was tightly clustered between $53.86 and $64.46 on routine volume of 4.0M–8.2M shares — a well-defined low-price, low-volume cluster. On 2026-08-19 a single bar obliterated that cluster: close $174.38 on 199.3M shares (+176.97%), a volume spike roughly 7.5× the trailing 20-day ADV of 26.4M. Rather than a clean cluster_break_up, this registers as a single-session climax; the two sessions that followed (2026-08-20: $133.32 on 99.5M, down 23.55%; 2026-08-21: $145.13 on 87.3M, up 8.86%) show price unable to hold the breakout level on still-massive volume — a hallmark of post-climax distribution at the highs. Today's bar (2026-08-25: $158.83 on 49.0M, z-score only +0.46 vs. the distorted 20-day mean) is a bounce off the 2026-08-24 low of $138.89, but the overall post-spike sub-path (08-19 → 08-25) shows net negative price movement from $174.38 to $158.83 on cumulatively enormous volume — criteria (1) and (2) for a bearish label are both met, satisfying the macro-rule threshold for the exhaustion call even in a potentially supportive rate environment. Risks: The exhaustion read would be invalidated if MRNA can reclaim and close above the 2026-08-19 climax high of $174.38 on expanding volume over multiple sessions, which would recast the spike as genuine demand absorption and open a new higher range. Additionally, if the catalyst behind the 08-19 gap (likely a major clinical/regulatory event) represents a durable, fundamental repricing, the SIR path-based framework may underweight the new information and the post-spike base could resolve bullishly.
- ✓Aug 25, 4:24 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
MRNA is down 10.1% from its 30-day high following what appears to be a pullback after a massive 179% rally driven by a melanoma therapy candidate catalyst. The company appears fundamentally sound with a transformative pipeline catalyst (mRNA melanoma therapy), and the Health Care sector is the second-strongest sector with strong 5d and 30d relative strength vs. SPY (+6.32pp). Today, Wolfe Research upgraded MRNA to Peer Perform and the stock is moving higher, suggesting some analyst support post-dip. The 10.1% dip looks like a normal profit-taking correction after an extraordinary run, not a fundamental deterioration.
- ✓Aug 25, 10:07 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — pyramid
Pyramid add-on fired at +10.23% unrealized. Added 4 sh @ $154.66 ($618.66). Position now 13 sh @ weighted avg $144.73.
- ▢Aug 24, 8:00 PMjournal
Agent 8 — Dip Buyer (Peer-Aware) opened long 7 @ $158.82
- ?Aug 24, 4:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.6% from its 30-day high, a meaningful but not anomalous dip for a volatile biotech. The drop is below the 35% triage threshold, so no artifact check is required. However, the evidence base is extremely sparse: no news headlines explain the catalyst, SEC filings carry no populated metrics, there is no insider activity, and no options flow data is available. Without a clear overreaction narrative or identifiable recovery catalyst, this cannot be scored as a high-conviction large-rebound candidate. The Health Care sector is ranked 4th of 11 by 30-day relative strength with a modest negative 30-day SPY spread (-0.99pts), suggesting the dip may be partly sector-driven but not dramatically so. Earnings are 72 days away (consensus EPS -$1.22), which removes imminent binary risk but also underscores that MRNA remains loss-making. Macro conditions (VIX at 6th percentile, 10Y at 4.65%) are calm but rates are elevated, a modest headwind for a cash-burning biotech.
- !Aug 24, 4:24 PMsignalseverity 0.21
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 20.6% from its 30-day high, a meaningful but not anomalous dip for a volatile biotech. The drop is below the 35% triage threshold, so no artifact check is required. However, the evidence base is extremely sparse: no news headlines explain the catalyst, SEC filings carry no populated metrics, there is no insider activity, and no options flow data is available. Without a clear overreaction narrative or identifiable recovery catalyst, this cannot be scored as a high-conviction large-rebound candidate. The Health Care sector is ranked 4th of 11 by 30-day relative strength with a modest negative 30-day SPY spread (-0.99pts), suggesting the dip may be partly sector-driven but not dramatically so. Earnings are 72 days away (consensus EPS -$1.22), which removes imminent binary risk but also underscores that MRNA remains loss-making. Macro conditions (VIX at 6th percentile, 10Y at 4.65%) are calm but rates are elevated, a modest headwind for a cash-burning biotech.
- ?Aug 24, 1:51 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down ~4% today, a meaningful move suggesting real selling conviction. However, several factors temper continuation confidence: (1) 115 minutes remaining is moderate — enough time for continuation but also enough for a partial mean-reversion bounce, especially after a sharp single-day gap-down move. (2) The headline noting 'gap down stocks in S&P500' suggests this may be part of a broader gap-down pattern today, which historically sees mixed follow-through — gap-downs sometimes fill intraday. (3) Macro context shows elevated 5-year forward inflation expectations (2.34, 1.8σ above trend), which is mildly risk-off and could weigh on growth/biotech names like MRNA, lending slight support to continued downside. (4) The volume deviation headline is ambiguous — abnormal volume could support continuation if it reflects heavy selling, but thin volume would argue for fade; without directional clarity, it's neutral. (5) No specific fundamental catalyst is identified, which means this could be sector/macro-driven selling rather than company-specific, making it somewhat stickier but also susceptible to broader market stabilization. On balance, the move has meaningful size and macro headwinds align modestly with continuation, but the gap-down nature and time remaining introduce reversal risk. Slight edge to continuation down, but only marginally above threshold.
- !Aug 24, 1:51 PMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
MRNA is down ~4% today, a meaningful move suggesting real selling conviction. However, several factors temper continuation confidence: (1) 115 minutes remaining is moderate — enough time for continuation but also enough for a partial mean-reversion bounce, especially after a sharp single-day gap-down move. (2) The headline noting 'gap down stocks in S&P500' suggests this may be part of a broader gap-down pattern today, which historically sees mixed follow-through — gap-downs sometimes fill intraday. (3) Macro context shows elevated 5-year forward inflation expectations (2.34, 1.8σ above trend), which is mildly risk-off and could weigh on growth/biotech names like MRNA, lending slight support to continued downside. (4) The volume deviation headline is ambiguous — abnormal volume could support continuation if it reflects heavy selling, but thin volume would argue for fade; without directional clarity, it's neutral. (5) No specific fundamental catalyst is identified, which means this could be sector/macro-driven selling rather than company-specific, making it somewhat stickier but also susceptible to broader market stabilization. On balance, the move has meaningful size and macro headwinds align modestly with continuation, but the gap-down nature and time remaining introduce reversal risk. Slight edge to continuation down, but only marginally above threshold.
- ✓Aug 24, 12:16 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Net signal score: +1. MRNA is down 20.6% from its 30-day high — a magnitude that qualifies as a mean-reversion candidate (+1) with no identified fundamental catalyst from filings (metrics are empty in the 10-Q/8-K, no guidance cut, no going-concern language). No hard vetoes triggered: earnings are 72 days away (clean runway, +1), but the 10Y yield at 4.65% is a structural headwind for a growth/biotech name (-1), and MRNA appears to be a single-stock idiosyncratic mover while the Health Care sector ranks 4th of 11 by relative strength and is modestly outperforming on a 5-day basis (-1 for idiosyncratic drop in outperforming sector). No insider buying, no unusual options flow, and no news headlines — all scored neutral per framework. Macro is low-VIX (6th percentile, benign), which is supportive. Net score of +1 with no fundamental impairment anchors probability near the base rate of 55-60%, slightly discounted for the idiosyncratic nature of the drop and elevated 10Y yield.
- ?Aug 24, 12:16 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 20.6% from its 30-day high, a meaningful but not anomalous dip for a volatile biotech. The drop is below the 35% triage threshold, so no artifact check is required. However, the evidence base is extremely sparse: no news headlines explain the catalyst, SEC filings carry no populated metrics, there is no insider activity, and no options flow data is available. Without a clear overreaction narrative or identifiable recovery catalyst, this cannot be scored as a high-conviction large-rebound candidate. The Health Care sector is ranked 4th of 11 by 30-day relative strength with a modest negative 30-day SPY spread (-0.99pts), suggesting the dip may be partly sector-driven but not dramatically so. Earnings are 72 days away (consensus EPS -$1.22), which removes imminent binary risk but also underscores that MRNA remains loss-making. Macro conditions (VIX at 6th percentile, 10Y at 4.65%) are calm but rates are elevated, a modest headwind for a cash-burning biotech.
- !Aug 24, 12:16 PMsignalseverity 0.21
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 20.6% from its 30-day high, a meaningful but not anomalous dip for a volatile biotech. The drop is below the 35% triage threshold, so no artifact check is required. However, the evidence base is extremely sparse: no news headlines explain the catalyst, SEC filings carry no populated metrics, there is no insider activity, and no options flow data is available. Without a clear overreaction narrative or identifiable recovery catalyst, this cannot be scored as a high-conviction large-rebound candidate. The Health Care sector is ranked 4th of 11 by 30-day relative strength with a modest negative 30-day SPY spread (-0.99pts), suggesting the dip may be partly sector-driven but not dramatically so. Earnings are 72 days away (consensus EPS -$1.22), which removes imminent binary risk but also underscores that MRNA remains loss-making. Macro conditions (VIX at 6th percentile, 10Y at 4.65%) are calm but rates are elevated, a modest headwind for a cash-burning biotech.
- ?Aug 24, 11:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is down 4.03% intraday with no headline catalyst visible, suggesting institutional flow or sector rotation rather than a news-driven spike that might reverse. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm for strong continuation: (1) 235 minutes remaining is ample time but also means the bulk of the session move may already be priced in — a 4% decline often exhausts initial sellers by mid-session; (2) No macro context directly pressures biotech/MRNA specifically — the elevated 5Y5Y inflation forward (2.33, +1.6σ) is modestly negative for growth/rate-sensitive names but MRNA is not a primary rate-sensitive play; (3) Absence of news cuts both ways — without a sustained catalyst narrative, momentum can fade as algorithmic mean-reversion kicks in on a stock that has moved this far; (4) No volume confirmation data provided, which prevents a high-conviction read. Balancing the real but potentially exhausted downward flow against lack of reversal triggers, this is a borderline continuation setup. Assigning 0.52 — slight lean toward continuation given the size of the move and no clear reversal evidence, but not high conviction.
- !Aug 24, 11:51 AMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
MRNA is down 4.03% intraday with no headline catalyst visible, suggesting institutional flow or sector rotation rather than a news-driven spike that might reverse. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm for strong continuation: (1) 235 minutes remaining is ample time but also means the bulk of the session move may already be priced in — a 4% decline often exhausts initial sellers by mid-session; (2) No macro context directly pressures biotech/MRNA specifically — the elevated 5Y5Y inflation forward (2.33, +1.6σ) is modestly negative for growth/rate-sensitive names but MRNA is not a primary rate-sensitive play; (3) Absence of news cuts both ways — without a sustained catalyst narrative, momentum can fade as algorithmic mean-reversion kicks in on a stock that has moved this far; (4) No volume confirmation data provided, which prevents a high-conviction read. Balancing the real but potentially exhausted downward flow against lack of reversal triggers, this is a borderline continuation setup. Assigning 0.52 — slight lean toward continuation given the size of the move and no clear reversal evidence, but not high conviction.
- ?Aug 11, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
HARD VETO FIRED — STEP 1 (Extreme Drop Without Sector Confirmation): MRNA is down 30.9% from its 30-day high, approaching the >35% veto threshold, and the Health Care sector (XLV) is ranked 2nd of 11 by 30-day relative strength and is outperforming the market (+1.15pts vs SPY over 30 days), meaning there is zero sector-wide explanation for this decline. This is a sharply idiosyncratic single-stock drop. Net signal score is approximately -1: the drop magnitude earns +1, no earnings within 30 days earns +1, but the sector outperformance while the single stock collapses earns -1 (idiosyncratic problem signal), and the 10Y yield at 4.69% (above 4.5%) earns -1 for this growth/biotech name. Additionally, there is no insider buying, no unusual call flow, no disclosed fundamental catalyst, and the 10-Q filed 2026-07-31 provides no financial metrics to assess. The override criteria for this severity of drop require all three of: a verified transient catalyst, cluster insider buying (≥3), and unusual call flow — none of which are present. Re-entry context also does not help: the recovery back to the prior stop-out price is ungrounded in any new disclosed evidence.
- !Aug 11, 7:03 AMsignalseverity 0.30
Agent 5 — Dip Buyer (Evolving) — dip_skipped
HARD VETO FIRED — STEP 1 (Extreme Drop Without Sector Confirmation): MRNA is down 30.9% from its 30-day high, approaching the >35% veto threshold, and the Health Care sector (XLV) is ranked 2nd of 11 by 30-day relative strength and is outperforming the market (+1.15pts vs SPY over 30 days), meaning there is zero sector-wide explanation for this decline. This is a sharply idiosyncratic single-stock drop. Net signal score is approximately -1: the drop magnitude earns +1, no earnings within 30 days earns +1, but the sector outperformance while the single stock collapses earns -1 (idiosyncratic problem signal), and the 10Y yield at 4.69% (above 4.5%) earns -1 for this growth/biotech name. Additionally, there is no insider buying, no unusual call flow, no disclosed fundamental catalyst, and the 10-Q filed 2026-07-31 provides no financial metrics to assess. The override criteria for this severity of drop require all three of: a verified transient catalyst, cluster insider buying (≥3), and unusual call flow — none of which are present. Re-entry context also does not help: the recovery back to the prior stop-out price is ungrounded in any new disclosed evidence.
- ?Aug 11, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 30.9% from its 30-day high — just below the 35% anomalous triage threshold — but the evidence base is extremely thin: no news headlines, no meaningful SEC filing metrics, no insider activity, and no options flow to explain the drop or signal recovery. The company is expected to report a consensus EPS of -$1.14 (loss), consistent with MRNA's ongoing post-COVID revenue contraction and heavy R&D burn. The 10-Q and 8-K filings from late July contain no disclosed metrics, offering no visibility into whether fundamentals are stabilizing or deteriorating further. Healthcare sector is relatively strong (rank 2/11), suggesting this is an idiosyncratic drop rather than sector-wide selling — which increases the likelihood of company-specific negative catalysts we cannot identify with current data.
- !Aug 11, 7:03 AMsignalseverity 0.30
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 30.9% from its 30-day high — just below the 35% anomalous triage threshold — but the evidence base is extremely thin: no news headlines, no meaningful SEC filing metrics, no insider activity, and no options flow to explain the drop or signal recovery. The company is expected to report a consensus EPS of -$1.14 (loss), consistent with MRNA's ongoing post-COVID revenue contraction and heavy R&D burn. The 10-Q and 8-K filings from late July contain no disclosed metrics, offering no visibility into whether fundamentals are stabilizing or deteriorating further. Healthcare sector is relatively strong (rank 2/11), suggesting this is an idiosyncratic drop rather than sector-wide selling — which increases the likelihood of company-specific negative catalysts we cannot identify with current data.
- ?Aug 10, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 30.9% from its 30-day high — just below the 35% anomalous triage threshold — but the evidence base is extremely thin: no news headlines, no meaningful SEC filing metrics, no insider activity, and no options flow to explain the drop or signal recovery. The company is expected to report a consensus EPS of -$1.14 (loss), consistent with MRNA's ongoing post-COVID revenue contraction and heavy R&D burn. The 10-Q and 8-K filings from late July contain no disclosed metrics, offering no visibility into whether fundamentals are stabilizing or deteriorating further. Healthcare sector is relatively strong (rank 2/11), suggesting this is an idiosyncratic drop rather than sector-wide selling — which increases the likelihood of company-specific negative catalysts we cannot identify with current data.
- !Aug 10, 6:05 PMsignalseverity 0.30
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 30.9% from its 30-day high — just below the 35% anomalous triage threshold — but the evidence base is extremely thin: no news headlines, no meaningful SEC filing metrics, no insider activity, and no options flow to explain the drop or signal recovery. The company is expected to report a consensus EPS of -$1.14 (loss), consistent with MRNA's ongoing post-COVID revenue contraction and heavy R&D burn. The 10-Q and 8-K filings from late July contain no disclosed metrics, offering no visibility into whether fundamentals are stabilizing or deteriorating further. Healthcare sector is relatively strong (rank 2/11), suggesting this is an idiosyncratic drop rather than sector-wide selling — which increases the likelihood of company-specific negative catalysts we cannot identify with current data.
- ?Aug 10, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
HARD VETO FIRED — STEP 1 (Extreme Drop Without Sector Confirmation): MRNA is down 30.9% from its 30-day high, approaching the >35% veto threshold, and the Health Care sector (XLV) is ranked 2nd of 11 by 30-day relative strength and is outperforming the market (+1.15pts vs SPY over 30 days), meaning there is zero sector-wide explanation for this decline. This is a sharply idiosyncratic single-stock drop. Net signal score is approximately -1: the drop magnitude earns +1, no earnings within 30 days earns +1, but the sector outperformance while the single stock collapses earns -1 (idiosyncratic problem signal), and the 10Y yield at 4.69% (above 4.5%) earns -1 for this growth/biotech name. Additionally, there is no insider buying, no unusual call flow, no disclosed fundamental catalyst, and the 10-Q filed 2026-07-31 provides no financial metrics to assess. The override criteria for this severity of drop require all three of: a verified transient catalyst, cluster insider buying (≥3), and unusual call flow — none of which are present. Re-entry context also does not help: the recovery back to the prior stop-out price is ungrounded in any new disclosed evidence.
- !Aug 10, 6:04 PMsignalseverity 0.30
Agent 5 — Dip Buyer (Evolving) — dip_skipped
HARD VETO FIRED — STEP 1 (Extreme Drop Without Sector Confirmation): MRNA is down 30.9% from its 30-day high, approaching the >35% veto threshold, and the Health Care sector (XLV) is ranked 2nd of 11 by 30-day relative strength and is outperforming the market (+1.15pts vs SPY over 30 days), meaning there is zero sector-wide explanation for this decline. This is a sharply idiosyncratic single-stock drop. Net signal score is approximately -1: the drop magnitude earns +1, no earnings within 30 days earns +1, but the sector outperformance while the single stock collapses earns -1 (idiosyncratic problem signal), and the 10Y yield at 4.69% (above 4.5%) earns -1 for this growth/biotech name. Additionally, there is no insider buying, no unusual call flow, no disclosed fundamental catalyst, and the 10-Q filed 2026-07-31 provides no financial metrics to assess. The override criteria for this severity of drop require all three of: a verified transient catalyst, cluster insider buying (≥3), and unusual call flow — none of which are present. Re-entry context also does not help: the recovery back to the prior stop-out price is ungrounded in any new disclosed evidence.
- ?Aug 10, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA is down ~31% from its 30-day high with no available news headlines to explain the move, and SEC filings (10-Q and 8-Ks) lack extractable metrics, leaving the cause of the drop ambiguous. Moderna remains a fundamentally real company with mRNA platform diversification efforts, but it faces persistent revenue headwinds as COVID vaccine demand has structurally declined and its pipeline (RSV, flu, oncology) has not yet generated meaningful revenue. The macro backdrop shows inflation expectations (T5YIE) running 1.5σ below trend, which is modestly risk-positive for growth equities but is more relevant to commodities/TIPS than a biotech like MRNA; without a clearly constructive broad-market signal or sector tailwind, the large drawdown is harder to fade confidently.
- !Aug 10, 6:04 PMsignalseverity 0.30
Agent 4 — Dip Buyer (Frozen) — dip_skipped
MRNA is down ~31% from its 30-day high with no available news headlines to explain the move, and SEC filings (10-Q and 8-Ks) lack extractable metrics, leaving the cause of the drop ambiguous. Moderna remains a fundamentally real company with mRNA platform diversification efforts, but it faces persistent revenue headwinds as COVID vaccine demand has structurally declined and its pipeline (RSV, flu, oncology) has not yet generated meaningful revenue. The macro backdrop shows inflation expectations (T5YIE) running 1.5σ below trend, which is modestly risk-positive for growth equities but is more relevant to commodities/TIPS than a biotech like MRNA; without a clearly constructive broad-market signal or sector tailwind, the large drawdown is harder to fade confidently.
- ?Aug 10, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
HARD VETO FIRED — STEP 1 (Extreme Drop Without Sector Confirmation): MRNA is down 30.9% from its 30-day high, approaching the >35% veto threshold, and the Health Care sector (XLV) is ranked 2nd of 11 by 30-day relative strength and is outperforming the market (+1.15pts vs SPY over 30 days), meaning there is zero sector-wide explanation for this decline. This is a sharply idiosyncratic single-stock drop. Net signal score is approximately -1: the drop magnitude earns +1, no earnings within 30 days earns +1, but the sector outperformance while the single stock collapses earns -1 (idiosyncratic problem signal), and the 10Y yield at 4.69% (above 4.5%) earns -1 for this growth/biotech name. Additionally, there is no insider buying, no unusual call flow, no disclosed fundamental catalyst, and the 10-Q filed 2026-07-31 provides no financial metrics to assess. The override criteria for this severity of drop require all three of: a verified transient catalyst, cluster insider buying (≥3), and unusual call flow — none of which are present. Re-entry context also does not help: the recovery back to the prior stop-out price is ungrounded in any new disclosed evidence.
- !Aug 10, 7:02 AMsignalseverity 0.31
Agent 5 — Dip Buyer (Evolving) — dip_skipped
HARD VETO FIRED — STEP 1 (Extreme Drop Without Sector Confirmation): MRNA is down 30.9% from its 30-day high, approaching the >35% veto threshold, and the Health Care sector (XLV) is ranked 2nd of 11 by 30-day relative strength and is outperforming the market (+1.15pts vs SPY over 30 days), meaning there is zero sector-wide explanation for this decline. This is a sharply idiosyncratic single-stock drop. Net signal score is approximately -1: the drop magnitude earns +1, no earnings within 30 days earns +1, but the sector outperformance while the single stock collapses earns -1 (idiosyncratic problem signal), and the 10Y yield at 4.69% (above 4.5%) earns -1 for this growth/biotech name. Additionally, there is no insider buying, no unusual call flow, no disclosed fundamental catalyst, and the 10-Q filed 2026-07-31 provides no financial metrics to assess. The override criteria for this severity of drop require all three of: a verified transient catalyst, cluster insider buying (≥3), and unusual call flow — none of which are present. Re-entry context also does not help: the recovery back to the prior stop-out price is ungrounded in any new disclosed evidence.
- ?Aug 10, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 30.9% from its 30-day high — just below the 35% anomalous triage threshold — but the evidence base is extremely thin: no news headlines, no meaningful SEC filing metrics, no insider activity, and no options flow to explain the drop or signal recovery. The company is expected to report a consensus EPS of -$1.14 (loss), consistent with MRNA's ongoing post-COVID revenue contraction and heavy R&D burn. The 10-Q and 8-K filings from late July contain no disclosed metrics, offering no visibility into whether fundamentals are stabilizing or deteriorating further. Healthcare sector is relatively strong (rank 2/11), suggesting this is an idiosyncratic drop rather than sector-wide selling — which increases the likelihood of company-specific negative catalysts we cannot identify with current data.
- !Aug 10, 7:02 AMsignalseverity 0.31
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
MRNA is down 30.9% from its 30-day high — just below the 35% anomalous triage threshold — but the evidence base is extremely thin: no news headlines, no meaningful SEC filing metrics, no insider activity, and no options flow to explain the drop or signal recovery. The company is expected to report a consensus EPS of -$1.14 (loss), consistent with MRNA's ongoing post-COVID revenue contraction and heavy R&D burn. The 10-Q and 8-K filings from late July contain no disclosed metrics, offering no visibility into whether fundamentals are stabilizing or deteriorating further. Healthcare sector is relatively strong (rank 2/11), suggesting this is an idiosyncratic drop rather than sector-wide selling — which increases the likelihood of company-specific negative catalysts we cannot identify with current data.
- ?Aug 7, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 30.9% from its 30-day high — just below the 35% anomalous triage threshold — but the evidence base is extremely thin: no news headlines, no meaningful SEC filing metrics, no insider activity, and no options flow to explain the drop or signal recovery. The company is expected to report a consensus EPS of -$1.14 (loss), consistent with MRNA's ongoing post-COVID revenue contraction and heavy R&D burn. The 10-Q and 8-K filings from late July contain no disclosed metrics, offering no visibility into whether fundamentals are stabilizing or deteriorating further. Healthcare sector is relatively strong (rank 2/11), suggesting this is an idiosyncratic drop rather than sector-wide selling — which increases the likelihood of company-specific negative catalysts we cannot identify with current data.
- ?Aug 7, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
HARD VETO FIRED — STEP 1 (Extreme Drop Without Sector Confirmation): MRNA is down 30.9% from its 30-day high, approaching the >35% veto threshold, and the Health Care sector (XLV) is ranked 2nd of 11 by 30-day relative strength and is outperforming the market (+1.15pts vs SPY over 30 days), meaning there is zero sector-wide explanation for this decline. This is a sharply idiosyncratic single-stock drop. Net signal score is approximately -1: the drop magnitude earns +1, no earnings within 30 days earns +1, but the sector outperformance while the single stock collapses earns -1 (idiosyncratic problem signal), and the 10Y yield at 4.69% (above 4.5%) earns -1 for this growth/biotech name. Additionally, there is no insider buying, no unusual call flow, no disclosed fundamental catalyst, and the 10-Q filed 2026-07-31 provides no financial metrics to assess. The override criteria for this severity of drop require all three of: a verified transient catalyst, cluster insider buying (≥3), and unusual call flow — none of which are present. Re-entry context also does not help: the recovery back to the prior stop-out price is ungrounded in any new disclosed evidence.
- ?Aug 7, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA is down ~31% from its 30-day high with no available news headlines to explain the move, and SEC filings (10-Q and 8-Ks) lack extractable metrics, leaving the cause of the drop ambiguous. Moderna remains a fundamentally real company with mRNA platform diversification efforts, but it faces persistent revenue headwinds as COVID vaccine demand has structurally declined and its pipeline (RSV, flu, oncology) has not yet generated meaningful revenue. The macro backdrop shows inflation expectations (T5YIE) running 1.5σ below trend, which is modestly risk-positive for growth equities but is more relevant to commodities/TIPS than a biotech like MRNA; without a clearly constructive broad-market signal or sector tailwind, the large drawdown is harder to fade confidently.
- ?Aug 7, 6:03 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[no_pattern] The 20-day PV path for MRNA tells a predominantly distributional story — a sustained slide from $67.44 (2026-07-14) down to a trough of $53.86 (2026-08-06) on persistent down-day volume dominance (e.g., -7.51% on 5.6M on 2026-07-16; -5.35% on a heavy 7.8M on 2026-07-31; -4.26% on 5.5M on 2026-08-06). Today's +9.86% close at $59.17 on 6.0M is an encouraging single-bar reversal, but volume (6.0M, z-score only 0.76 vs. the 20-day ADV of 5.1M) is only modestly above average — it does not constitute the materially expanding volume required to declare a clean cluster_break_up, and the prior cluster sits in the $53–$58 range rather than being a well-defined base. Because today's move is a single-session event lacking multi-session confirmation of accumulating demand, and the macro context (low T5YIE at 1.5σ below trend) favors inflation-defensive sectors rather than growth biotech, the SIR methodology's path-based discipline argues against a bullish call here. Risks: A failure to follow through above the $59–$60 level on comparable or higher volume over the next 2–3 sessions would confirm the single-bar nature of today's spike and reassert the dominant down-and-right distributional path. Additionally, the subdued macro inflation backdrop (T5YIE at 2.23, 1.5σ below trend) tilts sector rotation away from growth biotech, which could cap any recovery attempt and rapidly invalidate an accumulation thesis.
- ?Aug 7, 10:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MRNA is up 3.94% intraday with 345 minutes remaining (well over 5 hours), so there is ample time for continuation. The move is at the high end of the 2-5% range, suggesting real institutional flow behind it. No headlines are present, which is neutral — absence of news does not disqualify momentum. The macro context shows 5-year inflation expectations (T5YIE) running 1.5σ below trend, which is modestly risk-supportive (lower real rate fears) and does not pose a headwind for growth/biotech names like MRNA. However, the lack of a catalyst makes it harder to assign high conviction — without a known driver, sharp morning moves in biotech are prone to partial fades into the close as early buyers take profits. With no clear sector tailwind specific to biotech and no confirmatory news, this sits in the ordinary momentum bucket. Probability set modestly above 0.5 to favor the trade given bounded downside with the system's stop structure.
- ?Aug 7, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
HARD VETO FIRED: MRNA is down 37.1% from its 30-day high ($85.60 → $53.85), which exceeds the >35% isolation threshold. The Health Care sector (XLV) is NOT down >10% from its own 30-day high — in fact, the sector shows positive 30d relative strength vs. SPY (+2.42pts), confirming this is a severe single-stock idiosyncratic decline, not a sector-wide event. The three required override conditions are not met: (1) no verified, fully-disclosed transient catalyst — SEC filings contain no financial metrics and there are zero news headlines to explain the drop; (2) no cluster insider buying — zero Form 4 activity in the last 30 days; (3) no unusual call flow — no options data available. Net signal score: sector outperformance while stock collapses (-1), high 10Y yield at 4.63% above 4.5% threshold (-1) = net -2. Re-entry context: the prior stop-out at $59.34 is above current price, and the current level of $53.85 is above the original entry of $48.89, but no new grounded catalyst justifies re-entry given the magnitude of the unexplained drop.
- ?Aug 7, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 37.1% from its 30-day high — triggering the anomalous drop triage protocol. There are no confirming news headlines, no meaningful SEC filing metrics, no insider buying, and no options flow to validate a genuine price collapse or identify a recovery catalyst. The 10-Q and 8-K filed 2026-07-31 contain no extractable metrics, making it impossible to confirm fundamental soundness. The drop is more likely a data artifact (ex-dividend adjustment, spin-off, or data error) than a confirmed catastrophe, but without any corroborating evidence of a genuine dip-buy setup, the triage protocol mandates skepticism. Healthcare sector context is mildly positive (rank 3 of 11, +2.42pts 30d vs SPY), but this is insufficient to override the lack of any confirming signals for a company-specific recovery catalyst.
- ?Aug 6, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
HARD VETO FIRED: MRNA is down 37.1% from its 30-day high ($85.60 → $53.85), which exceeds the >35% isolation threshold. The Health Care sector (XLV) is NOT down >10% from its own 30-day high — in fact, the sector shows positive 30d relative strength vs. SPY (+2.42pts), confirming this is a severe single-stock idiosyncratic decline, not a sector-wide event. The three required override conditions are not met: (1) no verified, fully-disclosed transient catalyst — SEC filings contain no financial metrics and there are zero news headlines to explain the drop; (2) no cluster insider buying — zero Form 4 activity in the last 30 days; (3) no unusual call flow — no options data available. Net signal score: sector outperformance while stock collapses (-1), high 10Y yield at 4.63% above 4.5% threshold (-1) = net -2. Re-entry context: the prior stop-out at $59.34 is above current price, and the current level of $53.85 is above the original entry of $48.89, but no new grounded catalyst justifies re-entry given the magnitude of the unexplained drop.
- ?Aug 6, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 37.1% from its 30-day high — triggering the anomalous drop triage protocol. There are no confirming news headlines, no meaningful SEC filing metrics, no insider buying, and no options flow to validate a genuine price collapse or identify a recovery catalyst. The 10-Q and 8-K filed 2026-07-31 contain no extractable metrics, making it impossible to confirm fundamental soundness. The drop is more likely a data artifact (ex-dividend adjustment, spin-off, or data error) than a confirmed catastrophe, but without any corroborating evidence of a genuine dip-buy setup, the triage protocol mandates skepticism. Healthcare sector context is mildly positive (rank 3 of 11, +2.42pts 30d vs SPY), but this is insufficient to override the lack of any confirming signals for a company-specific recovery catalyst.
- ?Aug 6, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
MRNA is down 37.1% from its 30-day high with no news headlines available to explain the drop, making it difficult to attribute the decline to a specific catalyst. The SEC filings (10-Q and 8-Ks) have empty metrics, providing no financial detail to confirm or deny deterioration. While the absence of negative news is mildly constructive, Moderna has been in a sustained post-COVID revenue contraction cycle with ongoing cash burn, heavy R&D spend, and uncertain pipeline commercialization timelines — the structural backdrop is challenging even without fresh negative headlines. The macro signal (T5YIE well below trend) suggests a deflationary/risk-off tilt, which is not particularly supportive of speculative biotech names.
- ?Aug 6, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
HARD VETO FIRED: MRNA is down 33.4% from its 30-day high — approaching the >35% extreme-drop veto threshold — while the Health Care sector (XLV) is actually outperforming SPY on a 30-day basis (+4.40pts), confirming this is an idiosyncratic single-stock decline rather than a sector-wide dip. This isolation strongly suggests undisclosed distress or a structural negative catalyst. The three override conditions are not met: no cluster insider buying (zero Form 4 activity), no unusual call flow (no options data), and no verified transient catalyst in the filings (10-Q and 8-K metrics are empty, providing no exculpatory evidence). Net signal score: sector outperformance while stock craters (-1 idiosyncratic), high 10Y yield at 4.70% (-1), partially offset by no earnings imminent (+1) and neutral macro (+1), yielding a net score of 0 — insufficient to support a buy, and overridden by the near-veto drop magnitude in an isolated context. Re-entry is not supported: the prior thesis was exited at $59.34 and the stock has since fallen further with no grounding evidence of a new catalyst.
- ?Aug 6, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MRNA is down 33.4% from its 30-day high — just under the 35% anomalous-drop triage threshold, but still a very large move. Critically, there are zero confirming news headlines, no meaningful SEC filing metrics, no insider buying, and no options flow to explain or validate the decline. The 10-Q and 8-K filings lack any disclosed metrics, providing no fundamental anchor. With no identifiable catalyst for the drop and no confirmation signals, this setup has the hallmarks of either a data artifact or an unconfirmed negative catalyst — neither of which supports a high-conviction dip-buy. Health Care sector shows relative strength (rank 2/11, +4.40pts 30d vs SPY), suggesting the drop is idiosyncratic to MRNA rather than sector-driven, which increases the risk that company-specific bad news is behind the decline.
- ▣Jun 28, 8:00 PMjournaltarget
Agent 20 — SIR Price/Volume closed long 31 @ $69.70 (+$443.92)
Target hit: close $69.70 ≥ target $66.46
- ▣Jun 21, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 29 @ $59.35 (+$303.10)
Trailing stop on remainder: close $59.34 ≤ floor $59.48 (peak $63.96 × 0.93; floor at entry $48.89)
- ▣Jun 21, 8:00 PMjournalstop
options_momentum closed long 70 @ $10.29 (+$440.79)
Stop: premium $10.29 ≤ trailing floor $10.86 (peak $14.49 × 0.75)
- ▣Jun 16, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 28 @ $61.77 (+$360.63)
Staged exit (1/2.0): close $61.77 ≥ target $59.48. Selling 28/57 sh, trailing remainder.
- ▢Jun 15, 8:00 PMjournal
Agent 7 — Day Trader opened long 55 @ $53.52
- ▣Jun 15, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 55 @ $55.33 (+$99.55)
Long target: close $55.33 ≥ target $55.13
- ▣Jun 15, 8:00 PMjournaltarget
options_momentum closed long 30 @ $8.18 (+$125.69)
De-risk: premium $8.18 ≥ 2.0× entry $3.99. Selling 30/100 contracts; trailing the remainder.
- ▢Jun 15, 8:00 PMjournal
Agent 20 — SIR Price/Volume opened long 31 @ $55.38
- ▢Jun 11, 8:00 PMjournal
options_momentum opened long 30 @ $3.99
- ▢Jun 11, 8:00 PMjournal
options_momentum opened long 70 @ $3.99
- ▣Jun 10, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.52 (-$66.31)
Stop: premium $2.52 ≤ trailing floor $2.61 (peak $3.48 × 0.75)
- ▢Jun 9, 8:00 PMjournal
options_momentum opened long 100 @ $3.18
- ▣Jun 7, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.03 (-$205.79)
Stop: premium $2.03 ≤ trailing floor $3.07 (peak $4.09 × 0.75)
- ▢Jun 3, 8:00 PMjournal
options_momentum opened long 100 @ $4.09
- ▣Jun 2, 8:00 PMjournalstop
options_momentum closed long 200 @ $2.14 (-$247.70)
Stop: premium $2.14 ≤ trailing floor $2.79 (peak $3.71 × 0.75)
- ▢May 31, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 28 @ $48.89
- ▢May 31, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 29 @ $48.89
- ▢May 21, 8:00 PMjournal
options_momentum opened long 200 @ $3.38
- ▣May 20, 8:00 PMjournalstop
options_momentum closed long 200 @ $3.21 (-$22.63)
Stop: premium $3.21 ≤ trailing floor $3.39 (peak $4.53 × 0.75)
- ▢May 18, 8:00 PMjournal
options_momentum opened long 200 @ $3.32